Advertisement

Arrhythmias in Thyroid Disorders

  • Sonia Marrakchi Meziou
  • Emna Bennour
  • Faouzi Kanoun
  • Dania Idriss Marrakchi
  • Ikram Kammoun
  • Salem Kachboura
Chapter
  • 33 Downloads

Abstract

The most common clinical manifestations of thyrotoxic heart disease are heart rate disorders, in particular sinus tachycardia and atrial fibrillation, which are present in 28% of patients [1]. Typical arrhythmias found in hyperthyroidism are atrial premature contractions or atrial fibrillation, the latter occurring in 9–22% of patients [2]. Conversely, ventricular premature contractions are rare in this setting, and if present, their frequency is not decreased after treatment [3]. Malignant ventricular arrhythmias such as ventricular tachycardia or fibrillation, which are potentially fatal, are exceptional [4] and usually occur only in patients with marked heart failure or associated cardiac disease [5]. Surprisingly, there have been few population-based studies examining the long-term influence of thyroid disease and its treatment on morbidity and mortality [6].

Keywords

Arrhythmia Atrial fibrillation Ventricular tachycardia Thyroid disease Hypothyroid Hyperthyroid 

References

  1. 1.
    Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249–52.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Golf S, Løvstad R, Hansson V. Beta-adrenoceptor density and relative number of beta-adrenoceptor subtypes in biopsies from human right atrial, left ventricular, and right ventricular myocard. Cardiovasc Res. 1985;19(10):636–41.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Von Olshausen K, Bischoff S, Kahaly G, Mohr-Kahaly S, Erbel R, Beyer J, et al. Cardiac arrhythmias and heart rate in hyperthyroidism. Am J Cardiol. 1989;63(13):930–3.CrossRefGoogle Scholar
  4. 4.
    Roffi M, Cattaneo F, Brandle M. Thyrotoxicosis and the cardiovascular system. Minerva Endocrinol. 2005;30(2):47–58.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Polikar R, Burger AG, Scherrer U, Nicod P. The thyroid and the heart. Circulation. 1993;87(5):1435–41.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Osman F, Gammage MD, Sheppard MC, Franklyn JA. Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? J Clin Endocrinol Metab. 2002;87(3):963–7.PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Glass CK, Holloway JM. Regulation of gene expression by the thyroid hormone receptor. Biochim Biophys Acta. 1990;1032(2–3):157–76.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Brent GA. The molecular basis of thyroid hormone action. N Engl J Med. 1994;331(13):847–53.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Woeber KA. Thyrotoxicosis and the heart. N Engl J Med. 1992;327(2):94–8.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990;88(6):626–30.CrossRefGoogle Scholar
  11. 11.
    Klein I, Ojamaa K, Samarel AM, Welikson R, Hong C. Hemodynamic regulation of myosin heavy chain gene expression. Studies in the transplanted rat heart. J Clin Invest. 1992;89(1):68–73.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Danzi S, Klein S, Klein I. Differential regulation of the myosin heavy chain genes alpha and beta in rat atria and ventricles: role of antisense RNA. Thyroid. 2008;18(7):761–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Ojamaa K, Kenessey A, Klein I. Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology. 2000;141(6):2139–44.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Liu B, Huang F, Gick G. Regulation of Na,K-ATPase beta 1 mRNA content by thyroid hormone in neonatal rat cardiac myocytes. Cell Mol Biol Res. 1993;39(3):221–9.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Ojamaa K, Sabet A, Kenessey A, Shenoy R, Klein I. Regulation of rat cardiac Kv1.5 gene expression by thyroid hormone is rapid and chamber specific. Endocrinology. 1999;140(7):3170–6.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Davis PJ, Davis FB, Lin H-Y, Mousa SA, Zhou M, Luidens MK. Translational implications of nongenomic actions of thyroid hormone initiated at its integrin receptor. Am J Physiol Endocrinol Metab. 2009;297(6):E1238–46.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Bonow RO, Mann DL, Zipes DP, Libby P. Braunwald’s heart disease: a textbook of cardiovascular medicine. Elsevier Health Sciences;2011. 11033 p.Google Scholar
  18. 18.
    Sun ZQ, Ojamaa K, Nakamura TY, Artman M, Klein I, Coetzee WA. Thyroid hormone increases pacemaker activity in rat neonatal atrial myocytes. J Mol Cell Cardiol. 2001;33(4):811–24.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Hagiwara N, Irisawa H, Kasanuki H, Hosoda S. Background current in sino-atrial node cells of the rabbit heart. J Physiol. 1992;448:53–72.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hagiwara N, Irisawa H, Kameyama M. Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells. J Physiol. 1988;395:233–53.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Kodama I, Boyett MR, Nikmaram MR, Yamamoto M, Honjo H, Niwa R. Regional differences in effects of E-4031 within the sinoatrial node. Am J Physiol. 1999;276(3 Pt 2):H793–802.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Hüser J, Blatter LA, Lipsius SL. Intracellular Ca2+ release contributes to automaticity in cat atrial pacemaker cells. J Physiol. 2000;524(Pt 2):415–22.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Kiehn J, Karle C, Thomas D, Yao X, Brachmann J, Kübler W. HERG potassium channel activation is shifted by phorbol esters via protein kinase A-dependent pathways. J Biol Chem. 1998;273(39):25285–91.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Johnson PN, Freedberg AS, Marshall JM. Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial muscle cells in isolated atria of rabbits. Cardiology. 1973;58(5):273–89.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Sakaguchi Y, Cui G, Sen L. Acute effects of thyroid hormone on inward rectifier potassium channel currents in Guinea pig ventricular myocytes. Endocrinology. 1996;137(11):4744–51.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Apkon M, Nerbonne JM. Characterization of two distinct depolarization-activated K+ currents in isolated adult rat ventricular myocytes. J Gen Physiol. 1991;97(5):973–1011.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Sun ZQ, Ojamaa K, Coetzee WA, Artman M, Klein I. Effects of thyroid hormone on action potential and repolarizing currents in rat ventricular myocytes. Am J Physiol Endocrinol Metab. 2000;278(2):E302–7.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Levey GS, Klein I. Catecholamine-thyroid hormone interactions and the cardiovascular manifestations of hyperthyroidism. Am J Med. 1990;88(6):642–6.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Williams LT, Lefkowitz RJ, Watanabe AM, Hathaway DR, Besch HR Jr. Thyroid hormone regulation of beta-adrenergic receptor number. J Biol Chem. 1977;252(8):2787–9.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Morkin E, Flink IL, Goldman S. Biochemical and physiologic effects of thyroid hormone on cardiac performance. Prog Cardiovasc Dis. 1983;25(5):435–64.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Hoit BD, Khoury SF, Shao Y, Gabel M, Liggett SB, Walsh RA. Effects of thyroid hormone on cardiac beta-adrenergic responsiveness in conscious baboons. Circulation. 1997;96(2):592–8.CrossRefGoogle Scholar
  32. 32.
    N J, Francis J. Atrial fibrillation and hyperthyroidism. Indian Pacing Electrophysiol J. 2005;5(4):305–11.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Ojamaa K, Klein I, Sabet A, Steinberg SF. Changes in adenylyl cyclase isoforms as a mechanism for thyroid hormone modulation of cardiac beta-adrenergic receptor responsiveness. Metabolism. 2000;49(2):275–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Farre J. Philippe Coumel: a founding father of modern arrhythmology. Europace. 2004;6(5):464–5.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Freedberg AS, Papp JG, Williams EM. The effect of altered thyroid state on atrial intracellular potentials. J Physiol. 1970;207(2):357–69.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Chen Y-C, Chen S-A, Chen Y-J, Chang M-S, Chan P, Lin C-I. Effects of thyroid hormone on the arrhythmogenic activity of pulmonary vein cardiomyocytes. J Am Coll Cardiol. 2002;39(2):366–72.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Rubinstein I, Binah O. Thyroid hormone modulates membrane currents in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1989;340(6):705–11.PubMedCrossRefGoogle Scholar
  38. 38.
    Haïssaguerre M, Jaïs P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659–66.PubMedCrossRefGoogle Scholar
  39. 39.
    Chen YJ, Chen SA, Chen YC, Yeh HI, Chan P, Chang MS, et al. Effects of rapid atrial pacing on the arrhythmogenic activity of single cardiomyocytes from pulmonary veins: implication in initiation of atrial fibrillation. Circulation. 2001;104(23):2849–54.PubMedCrossRefGoogle Scholar
  40. 40.
    Komiya N, Isomoto S, Nakao K, Hayano M, Yano K. Electrophysiological abnormalities of the atrial muscle in patients with paroxysmal atrial fibrillation associated with hyperthyroidism. Clin Endocrinol (Oxf). 2002;56(1):39–44.CrossRefGoogle Scholar
  41. 41.
    Jao YTFN, Chen Y, Lee W-H, Tai F-T. Thyroid storm and ventricular tachycardia. South Med J. 2004;97(6):604–7.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Boccalandro C, López-Penabad L, Boccalandro F, Lavis V. Ventricular fibrillation in a young Asian man. Lancet. 2003;361(9367):1432.PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Fisher J. Thyrotoxic periodic paralysis with ventricular fibrillation. Arch Intern Med. 1982;142(7):1362–4.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Muñoz-Camacho JF, Sagristá-Sauleda J. Malignant ventricular arrhythmias as the initial manifestation of hyperthyroidism. Rev Esp Cardiol Engl Ed. 2007;60(4):449–50.CrossRefGoogle Scholar
  45. 45.
    Wei JY, Genecin A, Greene HL, Achuff SC. Coronary spasm with ventricular fibrillation during thyrotoxicosis: response to attaining euthyroid state. Am J Cardiol. 1979;43(2):335–9.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Biondi B, Fazio S, Coltorti F, Palmieri EA, Carella C, Lombardi G, et al. Clinical case seminar: reentrant atrioventricular nodal tachycardia induced by levothyroxine. J Clin Endocrinol Metab. 1998;83(8):2643–5.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Gross G, Lues I. Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1985;329(4):427–39.PubMedCrossRefGoogle Scholar
  48. 48.
    Jaeger JM, Houser SR, Freeman AR, Spann JF Jr. Effect of thyroid hormone on canine cardiac Purkinje fiber transmembrane potential. Am J Physiol. 1981;240(6):H934–40.PubMedPubMedCentralGoogle Scholar
  49. 49.
    Qu Z, Weiss JN. Dynamics and cardiac arrhythmias. J Cardiovasc Electrophysiol. 2006;17(9):1042–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Meo SD, de Martino Rosaroll P, Piro MC, De Leo T. Electrophysiological properties of the hyperthyroid rat heart. Arch Int Physiol Biochim Biophys. 1994;102(2):153–9.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Buscemi S, Verga S, Cottone S, Andronico G, D’Orio L, Mannino V, et al. Favorable clinical heart and bone effects of anti-thyroid drug therapy in endogenous subclinical hyperthyroidism. J Endocrinol Invest. 2007;30(3):230–5.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Polikar R, Goy JJ, Schlapfer J, Lemarchand-Beraud T, Biollaz J, Magnenat P, et al. Effect of oral triiodothyronine during amiodarone treatment for ventricular premature complexes. Am J Cardiol. 1986;58(10):987–91.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Tribulova N, Knezl V, Shainberg A, Seki S, Soukup T. Thyroid hormones and cardiac arrhythmias. Vascul Pharmacol. 2010;52(3–4):102–12.CrossRefGoogle Scholar
  54. 54.
    Surawicz B, Mangiardi ML. Electrocardiogram in endocrine and metabolic disorders. Cardiovasc Clin. 1977;8(3):243–66.PubMedPubMedCentralGoogle Scholar
  55. 55.
    Nademanee K, Singh BN, Hendrickson JA, Reed AW, Melmed S, Hershman J. Pharmacokinetic significance of serum reverse T3 levels during amiodarone treatment: a potential method for monitoring chronic drug therapy. Circulation. 1982;66(1):202–11.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Polikar R, Feld GK, Dittrich HC, Smith J, Nicod P. Effect of thyroid replacement therapy on the frequency of benign atrial and ventricular arrhythmias. J Am Coll Cardiol. 1989;14(4):999–1002.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Di Meo S, Venditti P, De Leo T. Effect of iodothyronines on electrophysiological properties of rat papillary muscle fibres. Horm Metab Res. 1997;29(5):225–30.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Schenck JB, Rizvi AA, Lin T. Severe primary hypothyroidism manifesting with torsades de pointes. Am J Med Sci. 2006;331(3):154–6.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Fredlund BO, Olsson SB. Long QT interval and ventricular tachycardia of “torsade de pointe” type in hypothyroidism. Acta Med Scand. 1983;213(3):231–5.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Unal O, Erturk E, Ozkan H, Kiyici S, Guclu M, Ersoy C, et al. Effect of levothyroxine treatment on QT dispersion in patients with subclinical hypothyroidism. Endocr Pract. 2007;13(7):711–5.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Lee JK, Lewis JA. Myxoedema with complete A-V block and Adams-Stokes disease abolished with thyroid medication. Br Heart J. 1962;24:253–6.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Chess-Williams R, Coker SJ. Ventricular fibrillation is reduced in hypothyroid rats with enhanced myocardial alpha-adrenoceptor responsiveness. Br J Pharmacol. 1989;98(1):95–100.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Friberg L, Werner S, Eggertsen G, Ahnve S. Rapid down-regulation of thyroid hormones in acute myocardial infarction: is it cardioprotective in patients with angina? Arch Intern Med. 2002;162(12):1388–94.CrossRefGoogle Scholar
  64. 64.
    Epstein FH, Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–9.CrossRefGoogle Scholar
  65. 65.
    Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med. 2004;164(15):1675–8.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Frost L, Vestergaard P. Alcohol and risk of atrial fibrillation or flutter: a cohort study. Arch Intern Med. 2004;164(18):1993–8.PubMedCrossRefPubMedCentralGoogle Scholar
  67. 67.
    Frost L, Vestergaard P, Mosekilde L, Mortensen LS. Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980–1999. Int J Cardiol. 2005;103(1):78–84.PubMedCrossRefPubMedCentralGoogle Scholar
  68. 68.
    Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7(6):481–93.CrossRefGoogle Scholar
  69. 69.
    Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116(15):1725–35.CrossRefGoogle Scholar
  70. 70.
    Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000;21(4):327–33.PubMedCrossRefPubMedCentralGoogle Scholar
  71. 71.
    Zhou Z-H, Ma L-L, Wang L-X. Risk factors for persistent atrial fibrillation following successful hyperthyroidism treatment with radioiodine therapy. Intern Med Tokyo Jpn. 2011;50(24):2947–51.CrossRefGoogle Scholar
  72. 72.
    Xiao P, Gao C, Fan J, Du H, Long Y, Yin Y. Blockade of angiotensin II improves hyperthyroid induced abnormal atrial electrophysiological properties. Regul Pept. 2011;169(1–3):31–8.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Shimizu T, Koide S, Noh JY, Sugino K, Ito K, Nakazawa H. Hyperthyroidism and the management of atrial fibrillation. Thyroid. 2002;12(6):489–93.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Kunii Y, Uruno T, Matsumoto M, Mukasa K, Noh J, Ito K, et al. Pharmacological conversion of atrial fibrillation in the patients of Graves’ disease. Tokai J Exp Clin Med. 2012;37(4):107–12.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Bagchi N, Brown TR, Parish RF. Thyroid dysfunction in adults over age 55 years. A study in an urban US community. Arch Intern Med. 1990;150(4):785–7.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249–52.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142:838–42.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Heeringa J, Hoogendoorn EH, Vander Deure WM, Hofman A, Peeters RP, Hop WC, et al. High-normal thyroid function and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med. 2008;168:2219–24.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med. 2007;167:928–34.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Ozturk S, Dikbas O, Baltacı D, Ozyasar M, Erdem A, Ayhan SS, et al. Evaluation of atrial conduction abnormalities and left atrial mechanical functions in patients with subclinical thyroid disorders. Endokrynol Pol. 2012;63(4):286–93.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Gen R, Akbay E, Camsari A, Ozcan T. P-wave dispersion in endogenous and exogenous subclinical hyperthyroidism. J Endocrinol Investig. 2010;33:88–91.CrossRefGoogle Scholar
  82. 82.
    Cetinarslan B, Akkoyun M, Canturk Z, Tarkun I, Kahranman G, Komsuoglu B. Duration of the P wave and P wave dispersion in subclinical hyperthyroidism. Endocr Pract. 2003;9:200–3.PubMedCrossRefPubMedCentralGoogle Scholar
  83. 83.
    Aras D, Maden O, Ozdemir O, Aras S, Topaloglu S, Yetkin E, et al. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. Int J Cardiol. 2005;99:59–64.PubMedCrossRefPubMedCentralGoogle Scholar
  84. 84.
    Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88:1672–7.PubMedCrossRefPubMedCentralGoogle Scholar
  85. 85.
    Biondi B, Fazio S, Palmieri EA, Tremalaterra R, Angellotti G, Bone F, et al. Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function. Cardiologia. 1999;44:443–9.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Sawin CT. Subclinical hypothyroidism in older persons. Clin Geriatr Med. 1995;11(2):231–8.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Klemperer JD, Klein IL, Ojamaa K, Helm RE, Gomez M, Isom OW, et al. Triiodothyronine therapy lowers the incidence of atrial fibrillation after cardiac operations. Ann Thorac Surg. 1996;61(5):1323–7; discussion 1328–9.CrossRefGoogle Scholar
  88. 88.
    Kim E-J, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ, et al. Relation of hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J. 2014;167(1):123–6.PubMedCrossRefPubMedCentralGoogle Scholar
  89. 89.
    Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Psaty BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab. 2015;100(3):1088–96.PubMedCrossRefPubMedCentralGoogle Scholar
  90. 90.
    Baumgartner C, da Costa BR, Collet TH, Feller M, Floriani C, Bauer DC, et al. Thyroid function within the normal range, subclinical hypothyroidism, and the risk of atrial fibrillation. Circulation. 2017;136(22):2100–16.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Petersen P, Hansen JM. Stroke in thyrotoxicosis with atrial fibrillation. Stroke J Cereb Circ. 1988;19(1):15–8.CrossRefGoogle Scholar
  92. 92.
    Siu CW, Pong V, Zhang X, Chan YH, Jim MH, Liu S, et al. Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. Heart Rhythm. 2009;6(2):169–73.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    de Souza MV, Dos Santos Teixeira PF, Vaisman M, Salles Xavier S. Is CHA2DS2-VASc appropriate for hyperthyroid patients with atrial fibrillation? Implications of adding a transesophageal echocardiography evaluation. Int J Cardiol. 2017;228:919–25.PubMedCrossRefPubMedCentralGoogle Scholar
  94. 94.
    Chan PH, Hai J, Yeung CY, Lip GY, Lam KS, Tse HF, Siu CW. Benefit of anticoagulation therapy in hyperthyroidism-related atrial fibrillation. Clin Cardiol. 2015;38(8):476–82.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Howard-Thompson A, Luckey A, George C, Choby BA, Self TH. Case report: Graves’ disease and treatment effects on warfarin anticoagulation. Case Rep Med. 2014, Article ID 292468, 6 pages.Google Scholar
  96. 96.
    Polmear JL, Hare MJ, Catford SR, Topliss DJ, Dooley MJ. Use of anticoagulation in thyroid disease. Aust Fam Physician. 2016;45(3):109–11.PubMedPubMedCentralGoogle Scholar
  97. 97.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Badawi O. Possible effect of thyroid function on anticoagulant response to unfractionated heparin. Pharmacotherapy. 2006;26(2):285–8.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med. 1982;72(6):903–6.PubMedCrossRefPubMedCentralGoogle Scholar
  100. 100.
    Singh BN. Amiodarone as paradigm for developing new drugs for atrial fibrillation. J Cardiovasc Pharmacol. 2008;52(4):300–5.PubMedCrossRefPubMedCentralGoogle Scholar
  101. 101.
    Narayana SK, Woods DR, Boos CJ. Management of amiodarone-related thyroid problems. Ther Adv Endocrinol Metab. 2011;2(3):115–26.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Bogazzi F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E. Amiodarone and the thyroid: a 2012 update. J Endocrinol Invest. 2012;35(3):340–8.Google Scholar
  103. 103.
    Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6(1):34–41.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med. 1995;332(3):162–73.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Denes P, Wu D, Dhingra RC, Chuquimia R, Rosen KM. Demonstration of dual A-V nodal pathways in patients with paroxysmal supraventricular tachycardia. Circulation. 1973;48(3):549–55.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Rosen KM, Mehta A, Miller RA. Demonstration of dual atrioventricular nodal pathways in man. Am J Cardiol. 1974;33(2):291–4.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Abbasoğlu A, Ecevit A, Tuğcu AU, Erdoğan L, Kınık ST, Tarcan A. Neonatal thyrotoxicosis with severe supraventricular tachycardia: case report and review of the literature. J Pediatr Endocrinol Metab. 2015;28(3–4):463–6.PubMedPubMedCentralGoogle Scholar
  108. 108.
    Lynch MJ, Woodford NWF. Sudden unexpected death in the setting of undiagnosed Graves’ disease. Forensic Sci Med Pathol. 2014;10(3):452–6.PubMedCrossRefPubMedCentralGoogle Scholar
  109. 109.
    Colzani RM, Emdin M, Conforti F, Passino C, Scarlattini M, Iervasi G. Hyperthyroidism is associated with lengthening of ventricular repolarization. Clin Endocrinol (Oxf). 2001;55(1):27–32.CrossRefGoogle Scholar
  110. 110.
    Davison ET, Davison MJ. Triiodothyronine (T3) toxicosis with hypokalemic periodic paralysis and ventricular tachycardia. J Electrocardiol. 1995;28(2):161–4.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    Dorian P, Cass D. An overview of the management of electrical storm. Can J Cardiol. 1997;13(Suppl A):13A–7A.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Erdogan HI, Gul EE, Gok H, Nikus KC. Therapy-resistant ventricular tachycardia caused by amiodarone-induced thyrotoxicosis: a case report of electrical storm. Am J Emerg Med. 2012;30(9):2092.e5–7.CrossRefGoogle Scholar
  113. 113.
    Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol Eur Fed Endocr Soc. 2005;152(1):1–9.CrossRefGoogle Scholar
  114. 114.
    Kaminski G, Makowski K, Michałkiewicz D, Kowal J, Ruchala M, Szczepanek E, Gielerak G. The influence of subclinical hyperthyroidism on blood pressure, heart rate variability, and prevalence of arrhythmias. Thyroid. 2012;22(5):454–60.CrossRefGoogle Scholar
  115. 115.
    Chojnowski K, Bielec A, Czarkowski M, Dmowska-Chalaba J, Kochanowski J, Wasowska A. Repeated ventricular. Cardiol J. 2007;14(2):198–201.PubMedPubMedCentralGoogle Scholar
  116. 116.
    Samuels MH. Subclinical thyroid disease in the elderly. Thyroid. 1998;8(9):803–13.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Bakiner O, Ertorer ME, Haydardedeoglu FE, Bozkirli E, Tutuncu NB, Demirag NG. Subclinical hypothyroidism is characterized by increased QT interval dispersion among women. Med Princ Pract. 2008;17(5):390–4.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Sonia Marrakchi Meziou
    • 1
  • Emna Bennour
    • 1
  • Faouzi Kanoun
    • 2
  • Dania Idriss Marrakchi
    • 3
  • Ikram Kammoun
    • 1
  • Salem Kachboura
    • 1
  1. 1.Cardiology DepartmentAbderrahman Mami HospitalArianaTunisia
  2. 2.Endocrinology DepartmentLa Rabta HospitalTunisTunisia
  3. 3.University Manar 2 of TunisTunisTunisia

Personalised recommendations